BioTime, Inc. (NYSEMKT:BTX)

CAPS Rating: 1 out of 5

Results 1 - 14 of 14

Recs

0
Member Avatar ShortSeller58 (49.85) Submitted: 5/24/2014 2:36:42 PM : Underperform Start Price: $2.35 BTX Score: -7.09

Never earned a penny. No different than the 100 other micro pharmaceutical. companies hoping to find the "next big thing." Short this stock until the cows come home!

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:22:00 PM : Underperform Start Price: $3.94 BTX Score: +51.17

Short. Biotech. Revs down slightly. Losses widening.

Recs

0
Member Avatar bshelton3 (48.26) Submitted: 2/8/2013 5:22:53 PM : Outperform Start Price: $4.28 BTX Score: -69.93

buy

Recs

1
Member Avatar BenLevin (< 20) Submitted: 12/20/2012 10:12:27 AM : Outperform Start Price: $3.45 BTX Score: -61.71

Like all early-stage biotechs, BioTime's success relies not on its ability to develop novel treatments, but to get them through clinical trial and regulatory testing. BTX isn't setup for that - so my assumption is that they demonstrate high potential with their adult-based stem cell lines, and sell the technology out. Still, be prepared for a loooooong wait.

Recs

0
Member Avatar yanngp (< 20) Submitted: 2/17/2012 6:46:26 PM : Outperform Start Price: $5.49 BTX Score: -97.75

Very long term investment

Recs

1
Member Avatar TMFBiologyFool (97.17) Submitted: 5/5/2011 6:24:34 PM : Underperform Start Price: $6.15 BTX Score: +104.77

http://www.fool.com/investing/general/2011/05/05/the-bearish-case-for-biotime.aspx

Recs

0
Member Avatar Brurobin (< 20) Submitted: 4/28/2011 3:34:05 PM : Outperform Start Price: $7.07 BTX Score: -109.01

Breakthrough technology.

Recs

0
Member Avatar psmitty (45.41) Submitted: 3/14/2011 11:17:10 AM : Outperform Start Price: $7.90 BTX Score: -120.47

Dr. West. CEO

Recs

1
Member Avatar dcooper101 (69.90) Submitted: 3/4/2011 9:23:27 AM : Outperform Start Price: $8.05 BTX Score: -116.52

This company has a market cap of less than $400 M and a pipeline of product candidates that, if successful, could easily generate sales in the hundreds of millions or even billions. The industry average P/S multiple for pharma & biotech is 3.31. If the company develops one successful $1B candidate and is bought out for half the average multiple, then you have at least a 3-bagger even after dilution.

Recs

0
Member Avatar rattlernum3 (< 20) Submitted: 10/10/2010 1:31:21 PM : Outperform Start Price: $5.47 BTX Score: -122.48

Regen medician is going to sci rocket if this stuff will by pass the big farma and fda money makers.
BTIM

Recs

0
Member Avatar ColourPurple (< 20) Submitted: 2/10/2010 7:24:04 PM : Outperform Start Price: $4.95 BTX Score: -133.27

Innovative and creative company that can change medicine as we know it

Recs

1
Member Avatar whatsupprahalad (< 20) Submitted: 10/20/2009 3:19:13 PM : Outperform Start Price: $5.10 BTX Score: -131.07

Biotime has Dr Michael West as its CEO
Biotime primary growth machine is going to be Stem cell related products and assays.

Stem cell industry has the following major issues.

1. Purity.
2. Scalability
3. Histocompatibility

Histocompatibility is basically the rejection issues that are faced when there is an organ transplant. Even at the stem cell level the body can identify foreign bodies(stem cells) and will try and destroy them. iPS (induced Pluripotent Stem cell) is the technology which overcomes this problem.

The patients skin cells have stem cells (that is why the skin can regenerate) BTIM has a process in place to convert skin stem cells into the generic "like" embryonic stem cell process and this process is vector (virus) free process and called iPS

2. Scalability issues has been dealt with ACTCellerate growth process of growing stem cells in a growth medium

3. Purity issues have been resolved by using shot gun cloning. ie the required stem cell is selected from the more than 140 different types of stem cells and the selected stem cell is then grown and since it is selected/purified before growth/cloning the cells are 100% of the required type.

Company is one step ahead of the industry and hence delay in recognition.. get in now and this is a long term play on the future of medicine (your own body can provide the medicine -skin graft which can cure all your ills.)

VERY VERY STRONG BUY!!! MULTI-BAGGER for sure!!

http://whatsup-stockideas.blogspot.com

=happy investing

Recs

0
Member Avatar Displacement (< 20) Submitted: 9/28/2009 4:58:21 PM : Underperform Start Price: $4.26 BTX Score: +125.31

Read Tasty's comment.

Recs

0
Member Avatar 10joejtn (< 20) Submitted: 9/21/2009 10:43:58 AM : Outperform Start Price: $5.75 BTX Score: -141.98

Stock is in an explosive stem cell industry and has demonstrated trial results and studies that surpass all others in this space.

Results 1 - 14 of 14

Featured Broker Partners


Advertisement